EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Practical Considerations for the Design, Conduct, and Reporting of Clinical Pharmacokinetic Drug–Drug Interaction Studies in Drug Development

Thomas M Polasek iD, John O Miners iD

The Journal of Clinical Pharmacology · 2026-11 · 66 (11)

DOI: 10.1002/jcph.70326 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Clinical Pharmacology, online erschienen am 01.11.2026. Verfasst von Thomas M Polasek und 1 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Medicine Use and Safety, Monash University, Melbourne, Australia. Hauptthemen laut MEDLINE: Drug Development, Pharmacokinetics, Research Design. Die Arbeit nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical pharmacokinetic drug–drug interaction (PK‐DDI) studies are frequently required in drug development when metabolizing enzymes and transporters determine pharmacokinetics. Drugs can be victims, perpetrators, or victims and perpetrators, of PK‐DDIs, so the clinical consequences of these interactions, particularly the risks of severe adverse effects and therapeutic failures leading to poor clinical outcomes, must be well understood prior to regulatory filings. In this Commentary, background information on PK‐DDIs is summarized to the point in drug development where the decision is made to conduct a human study. Practical considerations for the design and conduct of clinical PK‐DDI studies are then addressed sequentially, including guidance about study populations, the selection of probe drugs, their doses and durations, suitable study designs, the contentious issues with inclusion and exclusion criteria, which endpoints are the most important, and samples sizes and power estimates. Guidance on how results should be reported is given, including clinical study reports and scientific literature. Although intended primarily for the pharmaceutical industry, the key points apply across all sectors of drug development and are best considered together with regulatory guidelines on drug interaction studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DevelopmentPharmacokineticsResearch DesignHumansDrug InteractionsPharmaceutical Preparations

Stichwörter der Autor:innen

clinical pharmacokineticsdrug developmentdrug metabolizing enzymes and transportersdrug–drug interactionsphase 1 studies

Substanzen

Pharmaceutical Preparations

Autor:innen und Institutionen

  • Centre for Medicine Use and Safety, Monash University, Melbourne, Australia.
  • CMAX Clinical Research, Adelaide, Australia.
  • Discipline of Clinical Pharmacology, Flinders University College of Medicine and Public Health, Flinders University, Adelaide, Australia.

ORCID-Profile: Thomas M Polasek, John O Miners

Zitieren

APA

Polasek, T. M., & Miners, J. O. (2026). Practical Considerations for the Design, Conduct, and Reporting of Clinical Pharmacokinetic Drug–Drug Interaction Studies in Drug Development. The Journal of Clinical Pharmacology, 66(11). https://doi.org/10.1002/jcph.70326

Vancouver

Polasek TM, Miners JO. Practical Considerations for the Design, Conduct, and Reporting of Clinical Pharmacokinetic Drug–Drug Interaction Studies in Drug Development. The Journal of Clinical Pharmacology. 2026;66(11). doi:10.1002/jcph.70326

BibTeX
@article{Polasek2026,
  author = {Polasek, Thomas M and Miners, John O},
  title = {Practical Considerations for the Design, Conduct, and Reporting of Clinical Pharmacokinetic Drug–Drug Interaction Studies in Drug Development},
  journal = {The Journal of Clinical Pharmacology},
  year = {2026},
  volume = {66},
  number = {11},
  doi = {10.1002/jcph.70326}
}
Kostenlos starten →